Literature DB >> 26560751

Factors related to increased resting energy expenditure in men with liver cirrhosis.

César Prieto-Frías1, Marian Conchillo, Marina Payeras, Mercedes Iñarrairaegui, Delia Davola, Gema Frühbeck, Javier Salvador, Macarena Rodríguez, José Á Richter, Carmen Mugueta, María J Gil, Ignacio Herrero, Jesús Prieto, Bruno Sangro, Jorge Quiroga.   

Abstract

OBJECTIVE: Hypermetabolism in cirrhosis is associated with a high risk of complications and mortality. However, studies about underlying mechanisms are usually focussed on isolated potential determinants and specific etiologies, with contradictory results. We aimed at investigating differences in nutrition, metabolic hormones, and hepatic function between hypermetabolic and nonhypermetabolic men with cirrhosis of the liver. PATIENTS AND METHODS: We prospectively enrolled 48 male cirrhotic inpatients. We evaluated their resting energy expenditure (REE) and substrate utilization by indirect calorimetry, body composition by dual-energy X-ray absorptiometry, liver function, and levels of major hormones involved in energy metabolism by serum sample tests. Patients with ascites, specific metabolic disturbances, and hepatocellular carcinoma were excluded.
RESULTS: REE and REE adjusted per fat-free mass (FFM) were significantly increased in cirrhotic patients. Overall, 58.3% of cirrhotic patients were classified as hypermetabolic. Groups did not differ significantly in age, etiology of cirrhosis, liver function, presence of ascites, use of diuretics, β-blockers, or presence of transjugular intrahepatic portosystemic shunts. Hypermetabolic cirrhotic patients had lower weight, BMI (P<0.05), nonprotein respiratory quotient (P<0.01), leptin (P<0.05), and leptin adjusted per fat mass (FM) (P<0.05), but higher FFM% (P<0.05) and insulin resistance [homeostatic model assessment-insulin resistance (HOMA-IR)] (P<0.05). Only HOMA-IR, leptin/FM, and FFM% were independently related to the presence of hypermetabolism.
CONCLUSION: Hypermetabolic cirrhotic men are characterized by lower weight, higher FFM%, insulin resistance, and lower leptin/FM when compared with nonhypermetabolic men. HOMA-IR, FFM%, and leptin/FM were independently associated with hypermetabolism, and may serve as easily detectable markers of this condition in daily clinical practice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26560751     DOI: 10.1097/MEG.0000000000000516

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

Review 1.  Are Predictive Energy Expenditure Equations Accurate in Cirrhosis?

Authors:  Tannaz Eslamparast; Benjamin Vandermeer; Maitreyi Raman; Leah Gramlich; Vanessa Den Heyer; Dawn Belland; Mang Ma; Puneeta Tandon
Journal:  Nutrients       Date:  2019-02-04       Impact factor: 5.717

2.  NUTRIC and Modified NUTRIC are Accurate Predictors of Outcome in End-Stage Liver Disease: A Validation in Critically Ill Patients with Liver Cirrhosis.

Authors:  Ulrich Mayr; Julia Pfau; Marina Lukas; Ulrike Bauer; Alexander Herner; Sebastian Rasch; Roland M Schmid; Wolfgang Huber; Tobias Lahmer; Gonzalo Batres-Baires
Journal:  Nutrients       Date:  2020-07-17       Impact factor: 5.717

Review 3.  Malnutrition in Patients with Liver Cirrhosis.

Authors:  Julia Traub; Lisa Reiss; Benard Aliwa; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-02-07       Impact factor: 5.717

4.  The Challenges of Nutritional Assessment in Cirrhosis.

Authors:  Alessio Molfino; Sheeva Johnson; Valentina Medici
Journal:  Curr Nutr Rep       Date:  2017-07-18

5.  Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.

Authors:  Antonino Tuttolomondo; Domenico Di Raimondo; Chiara Bellia; Giuseppe Clemente; Rosaria Pecoraro; Carlo Maida; Irene Simonetta; Valerio Vassallo; Danilo Di Bona; Eliana Gulotta; Marcello Ciaccio; Antonio Pinto
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.